The 20 Best Merkel Cell Carcinoma Doctors Near Me in Ann Arbor, MI

Dr. Kelly Harms, MD, PhD, is a faculty member in the Department of Dermatology at the University of Michigan and the director of our Multi-disciplinary Cutaneous Oncology clinic. She provides patient care in our Cutaneous Surgery and Oncology clinical programs, including the Mohs surgery clinic and multidisciplinary melanoma and cutaneous oncology clinics located within the U-M Rogel Cancer Center. Dr. Harms is a board-certified dermatologist and ACGME Fellowship-trained Mohs Surgeon, with specialized training and expertise in treating high-risk skin cancer.Dr. Harms joined the Dermatology faculty in 2014, upon completing her ACGME procedural dermatology fellowship, with advanced training in melanoma and cutaneous surgery and oncology at the Rogel Cancer Center. Her clinical work is focused on Mohs surgery and associated reconstruction, as well as the complex management of patients seen within our Multidisciplinary Melanoma and Merkel Cell Programs.Dr. Harms received her medical degree from the University of Alabama School of Medicine and her Ph.D. degree from the Medical Scientist Training Program in the Department of Cell Biology at the University of Alabama at Birmingham. She completed her internship in the Department of Internal Medicine, University of Michigan Hospitals. She completed her dermatology residency, post-doctoral research training, and procedural dermatology fellowship in the Department of Dermatology, University of Michigan Medical School. Her clinical research is focused on skin cancer biology and epidemiology, and therapy. Dr. Harms is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, and Basal Cell Skin Cancer. Dr. Harms is board certified in Dermatology and Micrographic Dermatologic Surgery.

Dr. Christopher Bichakjian is professor of dermatology and chair of the Department of Dermatology at the University of Michigan Medical School.Dr. Bichakjian is a foremost expert in the field of cutaneous surgery and oncology. He has a special interest in Merkel cell carcinoma and established one of the first multidisciplinary programs in the world for this rare skin cancer in 2006. He has presented over 100 national and international invited lectures and visiting professorships, and authored or co-authored nearly 90 peer-reviewed publications with a primary focus on cutaneous oncology.Dr. Bichakjian received his medical degree from Radboud University in The Netherlands. After relocating to the US, he completed residency in dermatology and fellowship in micrographic surgery and cutaneous oncology at Michigan Medicine. He subsequently practiced Mohs surgery in private practice and served as adjunct faculty at Weill Medical College at Cornell University in New York City.In 2004, Dr. Bichakjian was recruited back to Ann Arbor to join the faculty in the Department of Dermatology at Michigan Medicine. He served as director of the UM Multidisciplinary Merkel Cell Carcinoma Program for more than a decade (2006-2017), In addition, he served as chief of the Division of Cutaneous Surgery and Oncology and as director of the Multidisciplinary Melanoma Program in the Rogel Cancer Center from 2017-2020. Dr. Bichakjian is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Merkel Cell Carcinoma, Basal Cell Skin Cancer, Melanoma, and Eccrine Porocarcinoma. Dr. Bichakjian is board certified in Dermatology and Micrographic Dermatologic Surgery.

After receiving my M.D. and Ph.D. at the University of Alabama at Birmingham, I came to the University of Michigan for residency training in Anatomic Pathology. During my residency and subsequent Dermatopathology fellowship, I became interested in mechanistic studies of cutaneous and soft-tissue malignancies. Upon completion of my fellowship in June 2012, I accepted a faculty position at UMHS with joint appointments in the Departments of Dermatology and Pathology, in which I continue to investigate molecular events in the pathogenesis of Merkel cell carcinoma and other cutaneous malignancies, while maintaining clinical effort in dermatopathology and molecular dermatopathology. Dr. Harms is rated as an Elite provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Merkel Cell Carcinoma, Tieche-Jadassohn Nevus, Melanoma, and Sebaceous Adenoma. Dr. Harms is board certified in Pathology-Anatomic and Dermatopathology.

In 2008, Dr. Dlugosz was named Poth Professor of Cutaneous Oncology in the Dermatology Department at the University of Michigan in Ann Arbor. He is Scientific Director of the Cutaneous Oncology Program of the University of Michigan Comprehensive Cancer Center. He received his M.D. at the Pennsylvania State University College of Medicine in 1984, did an internship at the Roger Williams General Hospital in Providence, RI, and completed his dermatology residency, including a year as Chief Resident, at the University of Pennsylvania in Philadelphia, in 1988. He received his post-doctoral training with Dr. Stuart Yuspa at the National Cancer Institute, where he subsequently established an independent research program prior to his recruitment to the University of Michigan in 1997.Dr. Dlugosz has received multiple awards, grants, and fellowships from the National Institutes of Health, American Cancer Society, American Association for Cancer Research, Society for Investigative Dermatology, and Dermatology Foundation. He was elected to the American Society for Clinical Investigation in 2002, has been included in the Best Doctors in America listing since 2003, and was elected to the American Dermatological Association in 2005.The National Institutes of Health and other scientific agencies frequently enlist Dr. Dlugosz as a grant reviewer. He is also an ad hoc reviewer for multiple scholarly journals, and is frequently invited to speak, or chair sessions, at major scientific meetings both in the United States and abroad. Dr. Dlugosz is an author on over 60 published papers.Dr. Dlugosz's basic research program is centered on two interrelated areas. He is investigating how the abnormal regulation of an embryonic signaling pathway, called the Hedgehog pathway, causes tumor development in skin and several other organs. In other studies, he is investigating the role of the Hedgehog pathway in development, growth, and regeneration of hair follicles and related structures. Dr. Dlugosz is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 88 other conditions, according to our data. His clinical expertise encompasses Cicatricial Pemphigoid, Pemphigus, Bullous Pemphigoid, and Pemphigus Vulgaris. Dr. Dlugosz is board certified in Dermatology.

Christopher Lao is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Lao is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, and Metastatic Uveal Melanoma.

Dr. May Chan obtained her medical degree from the State University of New York at Buffalo and was a Howard Hughes Research Scholar in 2005-2006. She completed residency training in Anatomic Pathology at Beth Israel Deaconess Medical Center in Boston, followed by a Dermatopathology fellowship at Harvard. She joined the University of Michigan in 2011 and is now a Professor of Pathology and Dermatology. She is the Interim Section Head for Dermatopathology, the Program Director for the Dermatopathology Fellowship, and the Medical Director of the Immunohistochemistry Laboratory. She also serves on the Test Development and Advisory Committee of the American Board of Pathology.Dr. Chan is an editorial board member of Modern Pathology and Journal of Cutaneous Pathology. She has a broad research interest in the areas of inflammatory skin diseases, melanocytic lesions, cutaneous adnexal neoplasms, and immunohistochemistry. She is the author/co-author of over 90 peer-reviewed publications and the book, Handbook of Direct Immunofluorescence: A Pattern-based Approach to Skin and Mucosal Biopsies.Dr. Chan is board certified in Anatomic Pathology and Dermatopathology. In addition to her primary role as a dermatopathologist, Dr. Chan retains her interest in surgical pathology including interpretation of head and neck, soft tissue, pulmonary, and endocrine cases, as well as intraoperative frozen sections. Over the years she has been invited to speak at national and international meetings hosted by the United States and Canadian Academy of Pathology (USCAP), the American Society of Dermatopathology (ASDP), the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), the American Academy of Dermatology (AAD), the European Nail Society, and Dermpedia. Dr. Chan is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Basal Cell Skin Cancer, Sebaceous Adenoma, and Squamous Cell Skin Carcinoma.

Dr. Angeles is an Associate Professor with Tenure of Surgery, Associate Professor of Dermatology, and Faculty Member in the Cancer Biology PhD Program at the University of Michigan in the Division of Surgical Oncology. She earned her medical degree at Tufts University School of Medicine. She completed general surgery residency at New York Presbyterian-Weill Cornell Medical Center. While in residency she completed a two-year basic/translational science Surgical Oncology Research Fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) focusing on the molecular biology and novel therapeutics for sarcoma. After residency, Dr. Angeles returned to MSKCC and completed a clinical Complex Surgical Oncology Fellowship. Dr. Angeles is board-certified in both General Surgery and Complex General Surgical Oncology. She is the Director of the Regional Cancer Therapies Clinic at University of Michigan/Rogel Cancer Center. Dr. Angeles is a nationally recognized surgeon-scientist dedicated to advancing cancer care through innovative research and compassionate patient care. As the lead investigator for multiple clinical trials at the Rogel Cancer Center, she is at the forefront of developing new treatments for melanoma and sarcoma. Her laboratory studies the immune system’s role in fighting cancer, with a special focus on how resident memory T cells can help create long-lasting protection against tumors. By combining basic science and translational research, Dr. Angeles and her team are working to transform discoveries in the lab into effective new therapies for patients. Dr. Angeles’s research has been supported by the American Cancer Society, the Melanoma Research Alliance, the Society of Surgical Oncology, and the National Institutes of Health’s National Cancer Institute (NCI-NIH).Committed to excellence in both science and patient care, Dr. Angeles is a Fellow of the American College of Surgeons, a Fellow of the Society of Surgical Oncology, and an active member of professional societies including the American Society of Clinical Oncology (ASCO), the Society of Surgical Oncology (SSO), the Connective Tissue Oncology Society (CTOS), and the Society for Immunotherapy of Cancer (SITC). She also serves as Chair of the Society of Surgical Oncology's Research Committee, helping to shape the future of cancer research and treatment.Clinical Specialization:Dr. Angeles is a board-certified surgical oncologist whose clinical practice focuses on patients with soft tissue cancers including sarcoma, melanoma, and non-melanoma cutaneous malignancies. Dr. Angeles cares for patients in a robust multidisciplinary fashion and provides education and counseling to her patients in order to allow shared decision making for the surgical management of their disease. Dr. Angeles is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Melanoma, Splenectomy, and Nephrectomy. Dr. Angeles is board certified in Surgery and Complex General Surgical Oncology.

Leslie Fecher, MD, joined the faculty on from Indiana University School of Medicine's Simon Cancer Center. Dr. Fecher completed her BA in Biochemistry at Rice University in Houston, and earned her MD from Indiana University School of Medicine. She completed her residency at University of Texas Southwestern in Dallas, followed by an Oncology Fellowship at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center in Baltimore. Dr. Fecher was an assistant professor of medicine at the Abramson Cancer Center in Philadelphia for four years where she held a secondary appointment in Dermatology. She subsequently joined the faculty at Indiana University in 2011. Dr. Fecher is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Tissue Biopsy.

Dr. James Hayman received his medical and master of business administration degrees simultaneously from the University of Chicago in 1991. Following an internship in Evanston, Ill., he began his radiation oncology residency at the Joint Center for Radiation Therapy at Harvard Medical School. He joined the University of Michigan faculty immediately following his residency in 1996 and currently serves as the director of the Clinical Division of the Department of Radiation Oncology. Dr. Hayman's clinical interests include the management of lung, esophageal, breast and central nervous system malignancies. He is also active in the area of health services research. Dr. Hayman is rated as a Distinguished provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Melanoma of the Eye, Merkel Cell Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Hayman is board certified in Radiation Oncology and Hospice & Palliative Med.

Dr. Elisabeth (Beth) Pedersen is an Assistant Professor in the Department of Dermatology at the University of Michigan. She is a board-certified dermatologist and provides patient care within our Multidisciplinary Cutaneous Oncology Clinic at the Taubman Center and Rogel Cancer Center.Dr. Pedersen specializes in advanced and high-risk skin cancer. She sees patients with Merkel cell carcinoma, melanoma, and advanced basal cell carcinoma. She also has a particular interest in rare skin cancers including dermatofibrosarcoma protuberans and other skin sarcomas.Dr. Pedersen received her Doctor of Medicine (MD) and Doctor of Philosophy (PhD) degrees through at the University of Michigan. She completed dermatology residency and postdoctoral research training at the University of Michigan Medical School. In addition to her clinical practice, she performs laboratory research focused on understanding the molecular and cellular biology of skin cancers, with the goal of identifying new strategies for cancer treatment. Dr. Pedersen is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Eccrine Porocarcinoma, Melanoma, and Sunburn.

Dr. Lowe received her undergraduate degree from Occidental College, Los Angeles, California in 1981 and her M.D. degree from the University of Texas Medical School at Houston, Houston, Texas in 1985. She did a transitional internship at St. Joseph's Hospital, Houston, Texas from 1985-1986 and then was a Post-doctoral Fellow in the Department of Dermatology at the University of Texas Medical School at Houston. From 1987-1989, she completed her residency training in dermatology at the University of Texas Medical School at Houston, followed by a Dermatopathology Fellowship at the University of Colorado School of Medicine, Denver, Colorado, from 1990-1991. Dr. Lowe is board certified in both Dermatology and Dermatopathology.In 1990, Dr. Lowe served as an Instructor in the Department of Dermatology at the University of Texas Medical School at Houston, Houston, Texas. She moved to the Department of Dermatology at Henry Ford Hospital, Detroit, Michigan, where she was a Senior Staff Physician and Director of Dermatopathology from 1991-1996. In 1996 she joined the faculty of the Departments of Pathology and Dermatology at the University of Michigan Medical School, Ann Arbor, Michigan, as Assistant Professor, where she was promoted to Associate Professor in 1998, and to Professor in 2004. She served as the Director of Dermatopathology in the Department of Pathology from 1996-2012.While at the University of Michigan Medical School, Dr. Lowe has been actively involved in the dermatopathology service, teaching and academic pursuits. She has been recognized institutionally and nationally as an educator and clinician. In 2013, Dr. Lowe received the Walter Nickel Teaching Award given by the American Society of Dermatopathology and also received the Outstanding Clinician of the Year Award bestowed by the University of Michigan Medical School. In 2015, she was inducted into the University of Michigan League of Clinical Excellence. Dr. Lowe received the William B. Taylor Resident Teaching Award from the Department of Dermatology, University of Michigan in 1999 and 2005 for exemplary teaching. She has been recognized annually since 2003 in America's Top Doctors for Cancer by Castle Connolly Medical Ltd. She has served on national committees, including the American Board of Dermatology, Dermatopathology Test Committee and the American Board of Pathology, Dermatopathology Test Committee and has served on the editorial boards of both the Journal of the American Academy of Dermatology and Cancer. Dr. Lowe is the author or co-author of more than 130 publications in peer-reviewed journals. Dr. Lowe is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Sebaceous Adenoma, Syringoma, and Syringocystadenoma Papilliferum. Dr. Lowe is board certified in Dermatology and Dermatopathology.

Dr. Jennifer Schwartz received her medical degree from Northwestern University Medical School and completed her internship in internal medicine at Northwestern Medical Center in Chicago. She completed her dermatology residency at the University of Michigan Department of Dermatology and two years of specialty training in melanoma at the U-M Rogel Cancer Center.Additionally, she completed advanced specialty training in cutaneous surgery treatment of benign and malignant lesions at the University of Michigan. In 1999, Dr. Schwartz became a faculty member of the Melanoma and Cutaneous Oncology and Surgery Program. Dr. Schwartz is rated as an Experienced provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Melanoma, Eccrine Porocarcinoma, Squamous Cell Skin Carcinoma, and Merkel Cell Carcinoma. Dr. Schwartz is board certified in Dermatology.

"Dr. Michael J. Davis is a Clinical Assistant Professor and board-certified Mohs surgeon and dermatologist in the Michigan Medicine Department of Dermatology. He provides expert care for patients with high-risk and advanced skin cancer in the Cutaneous Surgery and Oncology outpatient clinic at the UM Rogel Cancer Center and is a member of the multidisciplinary cutaneous oncology program.Dr. Davis graduated from the School of Medicine at Emory University, completed a dermatology residency at Dartmouth University, and pursued a Micrographic Surgery and Dermatologic Oncology clinical fellowship at Scripps Health in La Jolla, California. He completed a one-year Cutaneous Oncology Research Fellowship at Memorial Sloan Kettering Cancer Center, where he also served as an instructor of dermatology and interim assistant director of the Mohs lab for the Dermatology Service.Dr. Davis’s clinical and scholarly interests center on cutaneous surgery and oncology, with an emphasis on Mohs histopathology. He has co-authored seven chapters for the ""Laboratory Manual for Mohs Micrographic Surgery Frozen Tissue Processing,"" a comprehensive reference on the Mohs tissue processing technique (Springer, April 2024). He is an active member of the American Academy of Dermatology, the American Society for Dermatologic Surgery, the American College of Mohs Surgery, and the International Immunosuppression and Transplant Skin Cancer Collaborative.". Dr. Davis is rated as an Experienced provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Davis is board certified in Micrographic Dermatologic Surgery and Dermatology.

Timothy Johnson is a Dermatologist practicing medicine in Ann Arbor, Michigan. Dr. Johnson is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Melanoma, Squamous Cell Skin Carcinoma, Basal Cell Skin Cancer, and Merkel Cell Carcinoma.

Dr. Tasha Hughes is a Clinical Associate Professor of Surgery and a surgical oncologist at the University of Michigan. Her clinical efforts are focused on the treatment of breast cancer and melanoma. She is a health services research with a program centered around provider communication, provider bias and health care safety and quality.Dr. Hughes completed her surgical oncology training at Ohio State University Wexner Medical Center and James Comprehensive Cancer Society and her residency at Rush University Medical Center and John H. Stroger Hospital of Cook County in Chicago, IL. Dr. Hughes is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Lymphadenectomy.

Dr. Mierzwa has 8 years of clinical experience in treatment of head and neck as well as gastrointestinal cancers. Her clinical research interests have included novel chemoradiation regimens for head and neck cancers as well as pancreatic cancer. Specifically, she is currently in collaboration with the Department of Otolaryngology as part of a clinical trial to identify radiographic and serum biomarkers for oropharynx cancer patients who may be eligible for de-escalation of chemoradiation. Dr. Mierzwa is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Dry Mouth, and Pancreaticoduodenectomy. Dr. Mierzwa is board certified in Radiation Oncology.

Dr. Lesly Dossett, MD, MPH, is the Maud T. Lane Research Professor for Cancer Quality Improvement and Chief of the Division of Surgical Oncology at the University of Michigan. Dr. Dossett earned her medical degree from Vanderbilt University School of Medicine in 2003, having attended on a United States Navy Health Professions Scholarship. She completed her general surgery residency at Vanderbilt University in 2010, which included a health services research fellowship and completion of an MPH. After residency, Dr. Dossett served on active duty with the United States Navy in several roles stateside and overseas, including completing two deployments supporting combat operations in Afghanistan. After leaving the Navy in 2014, Dr. Dossett completed a clinical fellowship in Complex General Surgical Oncology at Moffitt Cancer Center and joined the faculty of the University of Michigan in 2016.Dr. Dossett specializes in treating patients with melanoma, soft tissue sarcoma, and breast cancer. Her research leverages implementation science frameworks and behavioral strategies to improve healthcare value. As co-director of the Michigan Program for Value Enhancement (MPrOVE), she works to translate value-based research findings into practice at Michigan Medicine and then scale those strategies more broadly to hospitals and healthcare systems. She is a principal investigator for R01s funded by the National Cancer Institute (NCI) and the Agency for Healthcare Research and Quality (AHRQ). She serves as a mentor on several federally funded training grants and career development awards.Dr. Dossett is an active member of several national societies. She serves as an officer in the Association for Academic Surgeons (AAS) and in the executive leadership of the American College of Surgeons (ACS) Cancer Research Program (CRP) and the Surgical Outcomes Club.Clinical Specialization:Dr. Dossett’s clinical focus is on melanoma and non-melanoma skin cancers, sarcoma, and breast cancer. She has expertise in locally and regionally advanced melanoma, breast angiosarcoma, retroperitoneal and pelvic sarcoma, breast conservation therapy, and skin and nipple sparing mastectomy. Dr. Dossett is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Retroperitoneal Liposarcoma, Melanoma, Desmoplastic Small Round Cell Tumor, Mastectomy, and Lymphadenectomy. Dr. Dossett is board certified in Surgery and Complex General Surgical Oncology.

Michael Englesbe, MD, FACS is the Cyrenus G Darling Sr M.D. and Cyrenus G Darling Jr M.D. Professor of Surgery at the University of Michigan in the Section of Transplantation Surgery. Dr. Englesbe received his undergraduate degree at Yale University in New Haven, Connecticut in 1993. He went on to obtain his medical degree in 1997 from the Robert Wood Johnson Medical School and completed his general surgery residency at the University of Michigan Health System in 2004. From 2000 to 2002, Dr. Englesbe did a surgical research post-doctoral fellowship at the University of Washington Medical Center in Seattle, Washington. He does kidney and liver transplantation in adults and children. He has a specific expertise in portal hypertension in children and adults.Education Focus:Dr. Englesbe particularly enjoys working with undergraduate students, medical students, and young physician trainees. He serves as the Department of Surgery Vice Chair for Resident Mentorship and the University of Michigan Medical School Capstone Curriculum Director.Clinical Specialization:Dr. Englesbe specializes in kidney and liver transplantation in adults and children. He has a specific expertise in portal hypertension in children and adults. Dr. Englesbe is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Hernia, Liver Failure, End-Stage Renal Disease (ESRD), Liver Transplant, and Kidney Transplant. Dr. Englesbe is board certified in Surgery.

Alfred Chang is a General Surgeon practicing medicine in Ann Arbor, Michigan. Dr. Chang is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Melanoma, Breast Cancer, Intraductal Papilloma, Mastectomy, and Lymphadenectomy.

Aleodor Andea is a Dermatologist practicing medicine in Ann Arbor, Michigan. Dr. Andea is rated as an Advanced provider by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Tieche-Jadassohn Nevus, Melanoma, Syringoma, and Basal Cell Skin Cancer.